Orlistat and acute kidney injury: an analysis of 953 patients.

Lewis), San Francisco General Hospital, San Francisco. Correspondence: Dr Fiebig, Clinical Laboratory, San Francisco General Hospital, Bldg NH, Room 2M24, 1001 Potrero Ave, San Francisco, CA 94110 (efiebig@ucsf.edu). Author Contributions: Study concept and design: Fiebig, Jones, Logan, Wang, and Lewis. Acquisition of data: Fiebig, Jones, Logan, Wang, and Lewis. Analysis and interpretation of data: Fiebig, Jones, and Lewis. Drafting of the manuscript: Fiebig. Critical revision of the manuscript for important intellectual content: Fiebig, Jones, Logan, Wang, and Lewis. Statistical analysis: Fiebig. Administrative, technical, and material support: Jones. Study supervision: Jones. Financial Disclosure: None reported.

[1]  Rapidly progressive renal failure associated with successful pharmacotherapy for obesity , .

[2]  M. Perazella,et al.  Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  P. Katzmarzyk.  The Canadian obesity epidemic, 1985-1998. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[4]  P. Shekelle,et al.  Meta-Analysis: Pharmacologic Treatment of Obesity , 2005, Annals of Internal Medicine.

[5]  Alain Golay,et al.  Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients , 1998, The Lancet.

[6]  A. Mokdad,et al.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. , 2003, JAMA.